Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
作者信息
Long G V, Flaherty K T, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalá M, Millward M, Arance A, Bondarenko I, Haanen J B A G, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies M A, Lane S R, Legos J J, Mookerjee B, Grob J-J
出版信息
Ann Oncol. 2019 Nov 1;30(11):1848. doi: 10.1093/annonc/mdz221.
Abstract
摘要
相似文献
1
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Ann Oncol. 2019 Nov 1;30(11):1848. doi: 10.1093/annonc/mdz221.
2
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Ann Oncol. 2017 Jul 1;28(7):1631-1639. doi: 10.1093/annonc/mdx176.
3
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF or BRAF mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.
Lancet Oncol. 2019 May;20(5):701-710. doi: 10.1016/S1470-2045(18)30940-9. Epub 2019 Mar 27.
4
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
Ann Oncol. 2022 Apr;33(4):406-415. doi: 10.1016/j.annonc.2021.12.014. Epub 2022 Jan 10.
5
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Lancet Oncol. 2018 Feb;19(2):181-193. doi: 10.1016/S1470-2045(18)30015-9. Epub 2018 Jan 18.
6
Trametinib: a MEK inhibitor for management of metastatic melanoma.
Onco Targets Ther. 2015 Aug 25;8:2251-9. doi: 10.2147/OTT.S72951. eCollection 2015.
7
Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11.
8
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.
Eur J Cancer. 2020 Jan;125:114-120. doi: 10.1016/j.ejca.2019.10.033.
9
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Clin Cancer Res. 2014 Apr 15;20(8):2035-43. doi: 10.1158/1078-0432.CCR-13-2054. Epub 2014 Feb 28.
10
Adverse Event Management in Patients with V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib.
Oncologist. 2019 Jul;24(7):963-972. doi: 10.1634/theoncologist.2018-0296. Epub 2018 Dec 31.
引用本文的文献
1
Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma.
Int J Mol Sci. 2025 Jan 20;26(2):861. doi: 10.3390/ijms26020861.
2
Precision Oncology in Melanoma: Changing Practices.
J Nucl Med. 2024 Dec 3;65(12):1838-1845. doi: 10.2967/jnumed.124.267781.
3
A cytosolic mutp53(E285K) variant confers chemoresistance of malignant melanoma.
Cell Death Dis. 2023 Dec 14;14(12):831. doi: 10.1038/s41419-023-06360-4.
4
Association of CDKN2A alterations with increased postoperative seizure risk after resection of brain metastases.
Neurosurg Focus. 2023 Aug;55(2):E14. doi: 10.3171/2023.5.FOCUS23133.
5
Current Patterns of Treatment and Outcomes in Advanced Melanoma at a Single Institution.
J Surg Res. 2023 Nov;291:25-33. doi: 10.1016/j.jss.2023.05.024. Epub 2023 Jun 16.
6
BRAF Mutations in CNS Tumors-Prognostic Markers and Therapeutic Targets.
CNS Drugs. 2023 Jul;37(7):587-598. doi: 10.1007/s40263-023-01016-5. Epub 2023 Jun 2.
7
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study.
Front Oncol. 2023 Feb 9;13:1107307. doi: 10.3389/fonc.2023.1107307. eCollection 2023.
8
Targeted Therapy for Melanomas Without BRAF V600 Mutation.
Curr Oncol Rep. 2022 Dec;24(12):1873-1881. doi: 10.1007/s11912-022-01306-z. Epub 2022 Nov 26.
9
Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients.
Cancers (Basel). 2022 Apr 24;14(9):2123. doi: 10.3390/cancers14092123.
10
International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral Centers.
Ann Surg. 2023 May 1;277(5):e1106-e1115. doi: 10.1097/SLA.0000000000005370. Epub 2023 Apr 6.
Zotero 插件